SCHEMBL23819181

SCHEMBL23819181

C[C@H](N)C(=O)O[C@H]1CCOC1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSL P07711 2/20 0.38
PDE4D Q08499 9/20 0.36
GPR119 Q8TDV5 1/20 0.33
MLNR O43193 1/20 0.32
ABCB11 O95342 1/20 0.32
LMNA P02545 1/20 0.32
CTSD P07339 1/20 0.32
CYP3A4 P08684 1/20 0.32
CYP3A5 P20815 1/20 0.32
CNR1 P21554 1/20 0.32
TBXAS1 P24557 1/20 0.32
ADRA1A P35348 1/20 0.32
ACACB O00763 3/20 0.32
PDE4A P27815 3/20 0.32
PDE4B Q07343 3/20 0.32
PDE4C Q08493 3/20 0.32
MAPK8 P45983 1/20 0.31
MAPK9 P45984 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
PIK3CD O00329 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23819043 1.00 CTSL (0.38) CTSLPDE4DGPR119MLNRABCB11
SCHEMBL31461598 1.00 CTSL (0.38) CTSLPDE4DGPR119MLNRABCB11
Hydrochloric Acid SCHEMBL30338425 0.98 CTSL (0.38) CTSLPDE4DGPR119MLNRABCB11
SCHEMBL720728 0.89 L3MBTL1 (0.38) LMNAACACBL3MBTL1PIK3CD
SCHEMBL720729 0.89 L3MBTL1 (0.38) LMNAACACBL3MBTL1PIK3CD
Hydrochloric Acid SCHEMBL17005254 0.87 L3MBTL1 (0.37) LMNAACACBL3MBTL1PIK3CD
Hydrochloric Acid SCHEMBL17005253 0.87 L3MBTL1 (0.37) LMNAACACBL3MBTL1PIK3CD
SCHEMBL30931383 0.86 CTSL (0.37) CTSLPDE4DGPR119MLNRABCB11
SCHEMBL8040912 0.85 CTSL (0.40) CTSLPDE4DGPR119ACACBPDE4A
SCHEMBL8035844 0.85 CTSL (0.40) CTSLPDE4DGPR119ACACBPDE4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11767337-B2 Antiviral compounds GILEAD SCIENCES, INC. (US) 2023-09-26 US disclosed
US-11767337-B2 Antiviral compounds GILEAD SCIENCES, INC. (US) 2023-09-26 US disclosed
US-20230295201-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. 2023-09-21 US disclosed
US-20230295201-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. 2023-09-21 US disclosed
US-20210284670-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. 2021-09-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295201-A1 ANTIVIRAL COMPOUNDS MAVS, HAVCR2, ZC3HAV1 CTSL 760/4885PDE4D 1783/4885GPR119 1269/4885
US-20210284670-A1 ANTIVIRAL COMPOUNDS MAVS, HAVCR2, ZC3HAV1 CTSL 760/4885PDE4D 1783/4885GPR119 1269/4885
US-11767337-B2 Antiviral compounds MAVS, HAVCR2, ZC3HAV1 CTSL 760/4885PDE4D 1783/4885GPR119 1269/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.